Prescribing a specific combined oral contraceptive (COC) to a female user is based on the dosage of estrogen, type of progestin generation and the dosage of these two compounds combined. Drospirenone (DRSP) is a novel steroidal progestin that has antimineralocorticoid and antiandrogenic effects and is an aldosterone antagonist. The synthetic estrogen 17α-ethinyl estradiol (EE) is commonly used in oral contraceptives and is considerably more active than natural estrogens. When DRSP and EE are used in combination in COCs, their properties have been suspected to be closer to natural progesterone levels and antiandrogenic and antimineralocorticoid effects. These hormones can cause platelet activation and also lead to a proaggregatable state of platelets. Erythrocytes play a vital role in venous thrombotic embolism in several ways by increasing the viscosity of blood and help direct platelets towards the damaged endothelium.
展开▼
